We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

The drugmaker’s U.S. plans comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% year ...

Then his mother, Alia Hayes, got some bad news. The manufacturer, GSK, was going to stop manufacturing the brand-name ...

GSK is leaving the biopharma trade group BIO, a spokesperson confirmed, the latest large pharma to back out of the group. “​​At this time, we believe there are other areas ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

BMI has predicted that naira will reach N1,993/$ by 2028, impacting Nigeria’s pharmaceutical industry’s ability to import ...

The Federal Government is advancing its commitment to ensure a self-sustaining healthcare system by collaborating with ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

Diabetes Singapore and GSK aim to enhance awareness and improve lives affected by diabetes through educational talks and activities on World Diabetes Day; 1 in 3 people will get s ...

(Reuters) -GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third quarter, ...